|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||330.191 g/mol g·mol−1|
|3D model (JSmol)|
Becampanel (INN) (code name AMP397) is a quinoxalinedione derivative drug which acts as a competitive antagonist of the AMPA receptor (IC50 = 11 nM). It was investigated as an anticonvulsant for the treatment of epilepsy by Novartis, and was also looked at as a potential treatment for neuropathic pain and cerebral ischemia, but never completed clinical trials.
|This anticonvulsant-related article is a stub. You can help Wikipedia by expanding it.|